GENETIC ENGINEERING, MILKHAUS JOINT VENTUREGenetic Engineering Inc. of Denver has formed a joint venturewith privately held Milkhaus Laboratories of Charleston, S.C.,to commercialize Milkhaus' animal health technology, includingits feline leukemia therapy and its anti-mastitis medicine. Thecompanies are negotiating to find a marketing partner. Nofurther details were disclosed.

The leukemia therapy is awaiting U.S. Department ofAgriculture marketing approval, and the mastitis medicine isin the final stages of development.

Genetic Engineering (OTC Bulletin Board:Geene) specializes inanimal reproductive technologies and animal health products.

COLGATE TO SELL IMMUNE RESPONSE STOCK

Colgate Palmolive Co. of New York has filed to sell 300,000shares of Immune Response Corp. stock (NASDAQ:IMNR).

A Colgate spokesman said the company makes no comments onstock sales.

Before the sale, Colgate owns 899,000 shares of Immunestock, or 6.7 percent of the company's shares. Colgate, whichhas had an investment in Immune since 1988, is the company'sthird-largest equity holder.

Stock of the San Diego company, which is developing drugs forautoimmune disorders, closed Friday at $10.88, up 50 cents.

TEVA COMPLETES SECONDARY OFFERING

Teva Pharmaceutical Industries Ltd. last weekcompleted asecondary offering of 4.5 million American Depositary Sharesat $12 per share. Of the shares, 3 million were sold by W.R.Grace & Co., which netted $35 million. Jerusalem-based Tevasold 1.5 million shares directly, grossing $18 million. Teva(NASDSAQ:TEVIY) closed at $12.75, up 25 cents, on Friday.

(c) 1997 American Health Consultants. All rights reserved.